A Phase 1, Placebo-Controlled Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2014
At a glance
- Drugs PF 5231023 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 21 May 2012 Actual patients number is 50 as reported by ClinicalTrials.gov.
- 21 May 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 21 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.